Program
HCP1306
A development code. Also written as “HCP1306 5/10mg”, “HCP1306 10/10mg” and “HCP1306 20/10mg”.
Its studies are mostly in Hypercholesterolemia, led by Hanmi Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hanmi Pharmaceutical | 61 open or running | phase 3since Jul 30, 2014 | Jul 30, 2014 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 30, 2014First study: phase 3 study in Primary HypercholesterolemiaFirst studyNCT02205606 · 412 enrolled · Korea, Republic of
- Oct 11, 2016Phase 1 study in Primary HypercholesterolemiaNCT02941848 · 60 enrolled
- Sep 2, 20192 phase 1 studies in HealthyNCT04081844, NCT04322266
- Jul 18, 2024Phase 1 study in HealthyNCT06518122 · 66 enrolled · Korea, Republic of
- Dec 9, 2025Phase 1 study in HealthyNCT07297693 · 60 planned · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07297693Healthy · South Korea | 1 | Not yet recruiting | Mar 25, 2026 | 60 |
| NCT06518122Healthy · Korea, Republic of | 1 | Completed | Jan 3, 2025 | 66 |
| NCT04322266Healthy · Korea, Republic of | 1 | Completed | Feb 13, 2019 | 61 |
| NCT04081844Healthy · Korea, Republic of | 1 | Completed | Jun 28, 2018 | 31 |
| NCT02941848Primary Hypercholesterolemia | 1 | Completed | Dec 2014 | 60 |
| NCT02205606Primary Hypercholesterolemia · Korea, Republic of | 3 | Completed | Feb 2015 | 412 |
How it is read
Names in the registry
- “HCP1306”, 5 entries
- “HCP1306 5/10mg”, 1 entry
- “HCP1306 10/10mg”, 1 entry
- “HCP1306 20/10mg”, 1 entry
Codes read as this program: HCP1306.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.